Journal of Neuro-Oncology

, Volume 81, Issue 2, pp 139–148

Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy


  • Stéphan Saikali
    • Département d’Anatomie et cytologie pathologiquesHôpital Pontchaillou
  • Tony Avril
    • UPRES EA3889, Université de Rennes 1
  • Brigitte Collet
    • Département de BiologieCentre Eugène Marquis
  • Abderrahmane Hamlat
    • Département de NeurochirurgieHôpital Pontchaillou
  • Jean-Yves Bansard
    • INSERM U642, Université de Rennes 1
  • Bernard Drenou
    • Département d’HématologieHôpital E. Muller
  • Yvon Guegan
    • Département de NeurochirurgieHôpital Pontchaillou
    • Département de BiologieCentre Eugène Marquis, and UPRES
Laboratory Investigation

DOI: 10.1007/s11060-006-9220-3

Cite this article as:
Saikali, S., Avril, T., Collet, B. et al. J Neurooncol (2007) 81: 139. doi:10.1007/s11060-006-9220-3


In this study, we investigated the mRNA and protein expression of nine tumour antigens in human glioblastoma multiforme with a view to their possible use in dendritic cell-based immunotherapy. Expression of ALK, EGFRvIII, GALT3, gp100, IL-13Rα2, MAGE-A3, NA17-A, TRP-2 and tyrosinase were studied by real-time RT-PCR on frozen tissues using a series of 47 tumour samples from patients with glioblastoma. Results were compared with non-neoplastic brain expression or glioblastoma samples with very low levels of expression near the limits of detection for EGFRvIII and MAGE-A3, as these latter two antigens were not detected in non-neoplastic brain. Tumour antigens showing a 5-fold increase in mRNA expression were considered as positive, and only antigens displaying an mRNA over-expression in a significant number of cases were analysed by immunohistochemistry on paraffin-embedded sections. Using real time RT-PCR, we found EGFRvIII, gp100, IL-13Rα2 and TRP-2 to be positive in 64, 38, 32 and 21% of cases, respectively. While we observed no over-expression for ALK, GALT3 and tyrosinase, 3 samples out of 47 were positive for MAGE-3 and 1 sample for NA17-A. More than 25% of tumour cells showed strong protein expression in 13, 34, 85 and 96% of GBM samples for gp100, TRP-2, EGFRvIII and IL-13Rα2, respectively. Interestingly, protein expression of at least 3 antigens was observed in 38% of cases. These results point out the importance of EGFRvIII, IL-13Rα2 and, to a less extent gp100 and TRP-2, for developing an immunotherapy strategy against glioblastoma.


GlioblastomaEGFRvIIIgp100IL-13Rα2TRP-2Dendritic cell-based immunotherapy



Cytotoxic T cell


Glioblastoma multiforme


Major histocompatibility complex

Copyright information

© Springer Science+Business Media B.V. 2006